Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$103.50
-0.1%
$95.84
$77.10
$163.71
$5.91B0.82737,185 shs289,937 shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$76.85
+0.8%
$69.41
$55.30
$94.99
$3.69B0.39673,113 shs249,556 shs
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$135.50
-0.5%
$134.12
$117.92
$196.26
$3.33B0.87260,296 shs152,204 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.71
-1.0%
$17.70
$14.17
$34.13
$1.97B0.721.13 million shs534,101 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+2.00%+11.25%+20.53%-15.00%
Haemonetics Corporation stock logo
HAE
Haemonetics
0.00%+3.89%+8.68%+30.33%-9.55%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.00%+2.79%+1.83%-4.75%+14.49%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%-1.64%+4.15%+6.59%+5.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Corporation stock logo
GKOS
Glaukos
4.5525 of 5 stars
4.41.00.04.43.51.70.6
Haemonetics Corporation stock logo
HAE
Haemonetics
4.883 of 5 stars
4.52.00.04.32.61.72.5
ICU Medical, Inc. stock logo
ICUI
ICU Medical
4.5226 of 5 stars
3.52.00.03.92.12.51.9
NovoCure Limited stock logo
NVCR
NovoCure
3.6026 of 5 stars
3.31.00.04.52.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6730.11% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.91
Moderate Buy$96.8025.97% Upside
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.00
Buy$192.6742.19% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8385.45% Upside

Current Analyst Ratings Breakdown

Latest NVCR, ICUI, GKOS, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/26/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$87.00
6/25/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/20/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/9/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$115.00 ➝ $105.00
5/9/2025
ICU Medical, Inc. stock logo
ICUI
ICU Medical
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$197.00 ➝ $187.00
5/8/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$104.00 ➝ $84.00
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $135.00
5/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $115.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M15.42N/AN/A$13.91 per share7.44
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.71$7.20 per share10.67$16.34 per share4.70
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$2.38B1.40$14.03 per share9.66$80.26 per share1.69
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.26N/AN/A$3.33 per share5.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3123.2215.251.2512.32%26.37%9.22%8/14/2025 (Estimated)
ICU Medical, Inc. stock logo
ICUI
ICU Medical
-$117.69M-$3.83N/A24.91N/A-3.87%6.75%3.20%8/6/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)

Latest NVCR, ICUI, GKOS, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
5/8/2025Q1 2025
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$1.23$1.72+$0.49-$0.63$574.15 million$599.49 million
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.75
2.59
1.52
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
96.10%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
6.40%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
1.50%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.48 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
ICU Medical, Inc. stock logo
ICUI
ICU Medical
15,00024.61 million24.24 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable

Recent News About These Companies

Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83
What Makes NovoCure (NVCR) a New Buy Stock
NovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Glaukos stock logo

Glaukos NYSE:GKOS

$103.50 -0.13 (-0.13%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$103.42 -0.08 (-0.07%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Haemonetics stock logo

Haemonetics NYSE:HAE

$76.84 +0.61 (+0.79%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$76.84 0.00 (0.00%)
As of 07/3/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

ICU Medical stock logo

ICU Medical NASDAQ:ICUI

$135.50 -0.68 (-0.50%)
Closing price 07/3/2025 01:48 PM Eastern
Extended Trading
$135.50 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.70 -0.18 (-0.98%)
Closing price 07/3/2025 03:48 PM Eastern
Extended Trading
$17.70 0.00 (0.00%)
As of 04:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.